Bad Miss For Biocon’s Bevacizumab In US But Firm In 'Good Place'

Bicara To Raise Funds In The Coming Fiscal Year

 
• By Anju Ghangurde
  
Pandemic induced misses dull momentum for Biocon • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip